Entecavir
- Generic Name
- Entecavir
- Brand Names
- Baraclude, Entecavir Viatris (previously Entecavir Mylan), Entecavir Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C12H15N5O3
- CAS Number
- 142217-69-4
- Unique Ingredient Identifier
- NNU2O4609D
- Background
Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS).
Entecavir is a guanine analogue that inhibits all three steps in the viral replication process, and the manufacturer claims that it is more efficacious than previous agents used to treat hepatitis B (lamivudine and adefovir). It was approved by the U.S. Food and Drug Administration (FDA) in March 2005.
- Indication
For the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
- Associated Conditions
- Chronic Hepatitis B Infection
- Associated Therapies
- -
Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B
- First Posted Date
- 2015-08-25
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 180
- Registration Number
- NCT02532413
- Locations
- 🇨🇳
Department of Infectious Disease of Wu Han Union Hospital, Wuhan, Hubei, China
Efficacy of HBV Vaccine in Consolidation of Nucleos(t)Ide Analogues Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 116
- Registration Number
- NCT02505009
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Taipei, Taiwan
A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis
- Conditions
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Shanghai Genomics, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT02499562
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China
Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT02482272
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
- Conditions
- Interventions
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT02452528
- Locations
- 🇺🇸
Kaiser Permanente, San Francisco, California, United States
🇺🇸Ichan School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Univ. Of Miami School Of Medicine/Center For Liver Diseases, Miami, Florida, United States
A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (HBV) Infection
- Conditions
- Interventions
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 31
- Registration Number
- NCT02391805
- Locations
- 🇲🇾
University Malaya Medical Center, Kuala Lumpur, Malaysia
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
Efficacies of Entecavir Add on HBeAg Positive Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment
- First Posted Date
- 2015-02-23
- Last Posted Date
- 2016-08-18
- Lead Sponsor
- Beijing Ditan Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT02368288
- Locations
- 🇨🇳
Beijing Ditan hospital,Capital Medical University, Beijing, Beijing, China
Efficacies of Entecavir Add on HBeAg Negative Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment
- First Posted Date
- 2015-02-18
- Last Posted Date
- 2016-08-19
- Lead Sponsor
- Beijing Ditan Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT02365402
- Locations
- 🇨🇳
Beijing Ditan hospital,Capital Medical University, Beijing, Beijing, China
Combination Therapy With Interferon Plus Interleukin 2 and Hepatitis B Vaccine in Chronic Hepatitis B Patients
- Conditions
- Interventions
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 94
- Registration Number
- NCT02360592
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳BeiJing YouAn Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳First Hospital, Beijing University, Beijing, Beijing, China
A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase
- Conditions
- Interventions
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2020-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 62
- Registration Number
- NCT02263079
- Locations
- 🇧🇪
Cliniques Universitaires St-Luc, Bruxelles, Belgium
🇮🇹Azienda Ospedaliero-Universitaria Policlinico S. Orsola Malpighi; U.O. Malattie Infettive, Bologna, Emilia-Romagna, Italy
🇩🇪Universitätsklinikum Essen; Klinik für Kinder- und Jugendmedizin Pädiatrie II, Essen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.